Companies › Spur Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Metabolic and endocrine; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FLT201 AAV-mediated gene therapy delivering functional GBA gene | GBA | Phase 3 | Gaucher Disease Type 1; Gaucher Disease, Type 1 | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07223944 | FLT201 | Phase 3 | Gaucher Disease Type 1 | Metabolic and endocrine | Jul 2028 |
| NCT06545136 | FLT201 | Phase 1 | Gaucher Disease, Type 1 | Metabolic and endocrine | May 2029 |
Lingyi Biotech Prevail Therapeutics Azafaros Bial R&D Investments
iECURE Yong Zhao, MD, PhD Grace Science Orchard Therapeutics BioLab Holdings
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.